Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04166565
Title Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease (EMN19)
Acronym EMN19
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors European Myeloma Network
Indications
Therapies
Age Groups: adult | senior
Covered Countries TUR | ITA | GRC


No variant requirements are available.